ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed the Investors Presentation on the Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2023. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Outcome Of Financial Results
The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia Approved the Audited Financial Results for the quarter and financial year ended''31st March, 2023. and Recommended a dividend of Rs. 8/- (400%) per Equity Share. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Outcome for Outcome Of Board Meeting
the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today Approved the Audited Financial Results for the quarter and financial year ended'' 31st March, 2023, Recommended a dividend of Rs. 8/- (400%) per Equity Share. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Change in Directorate
We would like to inform the exchange that based on the recommendation of Nomination and Remuneration Committee and the Board of Directors, the shareholders of the Company at their 12th Annual General Meeting of the Company held on 11th November, 2022 had approved the re-appointment of Mr. Shaunak Amin (DIN: 00245523) as Managing Director of the Company liable to retire by rotation for a period of 5 years w.e.f. 2nd May, 2023. The proceedings of the aforesaid Annual General Meeting were submitted with the Stock exchanges on 11th November, 2022. In this regard, we hereby declare that Mr. Shaunak Amin is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company ALEMBIC PHARMACEUTICALS LTD. 2 CIN NO. L24230GJ2010PLC061123 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* F.Y. 2022-23 & 2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2021-22, 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Manisha SarafDesignation :-Company Secretary Name of the Chief Financial Officer :- R K Baheti Designation : -Director Finance and CFO Date: 26/04/2023 ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyALEMBIC PHARMACEUTICALS LTD. 2CIN NO.L24230GJ2010PLC061123 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manisha Saraf Designation: Company Secretary EmailId: manisha.saraf@alembic.co.in Name of the Chief Financial Officer: R K Baheti Designation: Director Finance and CFO EmailId: rajkumar_baheti@alembic.co.in Date: 26/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Ref: Our earlier intimation dated 24th April, 2023 The exchange is hereby informed that the Company's Post Results Conference Call will be held on Friday, 5th May, 2023 at 5:30 p.m., as per the revised details enclosed. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
With reference to the captioned subject, we enclose herewith, a copy of newspaper advertisement related to notice for claiming shares from Company's Unclaimed Suspense Account published on 25th April, 2023 in English language newspaper. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on Friday, 5th May, 2023 as per the enclosed details.